Buyout Potential - SLS Vs PAND (MRK Just Bought Them For $1.85 Billion)
Summary
- PAND gets bought out by Merck for $1.85 Billion.
- SLS has trails in Phase 1, 2, and 3 while PAND only has Phase 1.
- SLS grossly undervalued and only has a $102 million market cap.
PAND gets bought out this morning for $1.85 billion... yes you read that right $1.85 billion for the following pipeline:
Zero assets in phase 2 or phase 3 trials...
Meanwhile, SLS has the following pipeline:
We actually have trials ongoing in phases 1, 2, and 3.
SLS has a market cap of 102.74 Million with a share price of $8.72 and float of 11.78 million.
SLS should be a prime buyout target by MRK or BMY or Roche, all of which are partners of theirs.
To extrapolate, a buyout of anywhere close to $1.5-$1.75 billion which is what they are worth would put the share price north of $127, a 1,356% increase.
SLS has multiple catalysts coming in the next two weeks with trial data being released, first-ever positive earnings per share, and by the way, they recently signed a $200 million licensing deal with China for GPS (Galinpepimut-S). Another reason for a buyout because it would give big pharma instant access to the Chinese market which is hard to get into. They have plenty of cash on hand, no debt, and a very small burn rate.
You know why it's so cheap because we have douche bag shorts like Citadel pushing it down and targeting it for years. They have been attacking this cancer cure for years. It's time to make them pay the price for over 2 million short shares and manipulation.
Analyst's Disclosure: I am/we are long SLS.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.